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The Big Picture on
Obesity and Insulin Resistance*
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London, United Kingdom
In this issue of the Journal, Abbasi et al. (1) use data from
previous studies in 314 individuals to quantify the relation-
ship between body mass index (BMI) and insulin resistance
and the relationship between these two factors and other
coronary heart disease (CHD) risk factors. The modified
insulin suppression test, previously validated by this group,
was used to define whole body insulin resistance. The main
findings were that only about a quarter of the variability in
insulin resistance was explicable by BMI. Second, at any
BMI those individuals classified as insulin-resistant had
higher insulin levels and were more glucose intolerant than
insulin-sensitive individuals. Third, of the risk factors ex-
amined, low high-density lipoprotein (HDL)-cholesterol
and hypertriglyceridemia were most strongly associated with
insulin resistance.
See page 937
Some aspects of methodology of this study, or series of
studies, mean that the surprisingly low estimate of 22%
variability in insulin resistance being explained by obesity
may be conservative. First, individuals with diabetes, CHD,
and hypertension were excluded. Because these conditions
are related to both BMI and insulin resistance, exclusion of
such individuals is likely to push the observed correlation
between BMI and insulin resistance downward. So too will
measurement error, which is likely here because only single
measurements of BMI and insulin resistance have been
taken. Third, BMI is not a perfect measure of adiposity.
However, although 22% may be an underestimate, the main
conclusion still holds; substantially less of the variance in
insulin resistance or sensitivity than previously believed is
likely to be attributable to obesity. Importantly, these data
support the previous result from the European Group for
the study of Insulin Resistance (EGIR) study, which used
the gold standard hyperinsulinemic euglycemic clamp
method for defining insulin resistance. In that study too,
only about a quarter of the variability in insulin resistance
could be explained by BMI (2).
Beyond total body fat mass, a tendency towards central
deposition of body fat as measured by increased waist-hip
ratio is thought to be a feature of, or a determinant of,
insulin resistance (3,4). Central fat deposition may reflect
visceral obesity. However, the importance of visceral obesity
remains controversial (5), and an independent association
between waist-hip ratio and insulin resistance was not
observed in the EGIR study. Given the controversy, it is
unfortunate that Abbasi’s large study was not able to provide
any information on this issue.
So why are some individuals apparently resistant to the
effect of obesity on insulin sensitivity, and why are others
insulin-resistant despite apparently being thin? The answer
may yet lie with fat. A considerable body of evidence now
points towards intramyocellular lipid (IMCL) content, as
measured by nuclear magnetic resonance spectroscopy, as
being a critical determinant of insulin resistance (6,7). The
correlation between IMCL and insulin resistance as mea-
sured by the hyperinsulinemic euglycemic clamp is much
higher than the correlation of BMI with insulin resistance
(6). While BMI is positively correlated with IMCL, some
people have high IMCL despite having a fairly low BMI
and vice versa. In several studies those subjects who were
insulin-resistant despite being thin had high IMCL. Such
individuals might be considered to be “metabolically obese.”
An extreme example of the importance of IMCL is seen in
congenital lipodystrophy where, because of a lack of adipose
tissue, postprandially free fatty acids are directed to other
tissues including myocytes with consequent accumulation of
IMCL and insulin resistance (8). Beyond obesity the
determinants of IMCL in the general population are as yet
unclear.
Abbasi et al. (1) conclude that it is self-evident that efforts
to reduce diabetes and CHD in overweight and obese
people should target those who are insulin-resistant. They
show that among insulin-resistant but not insulin-sensitive
individuals, those with higher BMI are less glucose-tolerant
and have higher insulin. The not unexpected implication of
these data is that prevention of diabetes through weight
reduction is more likely in overweight people who are
already on their way to becoming diabetic than those who
are not. But what does this actually mean for clinical
practice? Screening for insulin resistance in a clinical setting
is not feasible at present—there is no consensus on a
clinically applicable test for, or definition of, insulin resis-
tance. Even assuming that insulin-resistant individuals
could be identified easily, what interventions are cost-
effective for preventing diabetes? The Diabetes Prevention
Program in the U.S. and the Diabetes Prevention Study in
Finland have recently demonstrated that lifestyle modifica-
tion programs and metformin can delay the onset of
diabetes in glucose-intolerant individuals (9,10) but that
achieving increased physical activity and maintaining weight
reduction requires intensive and expensive interaction with
patients. We do not yet know how feasible, effective, or
affordable the nonpharmacologic interventions are outside
of the trial setting. Because the implementation of programs
for preventing diabetes in glucose-intolerant patients is in
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its infancy, extending these interventions to those insulin-
resistant overweight or obese subjects who are not yet
glucose-intolerant would seem to be some way off.
In the study by Abbasi et al. (1), those with higher BMI
had a worse risk factor profile, the slope of the relation being
similar among insulin-resistant and sensitive individuals for
systolic blood pressure (SBP), total and low-density lipopro-
tein cholesterol and triglyceride, and being steeper among
insulin-sensitive subjects for HDL cholesterol. The usual
caveats about inference from cross-sectional data notwith-
standing, these data suggest that that weight reduction
would be expected to achieve a similar reduction in SBP,
total cholesterol, and triglyceride, and perhaps a greater
increase in HDL cholesterol, in insulin-sensitive as resistant
individuals. So the data do not support the idea that only
insulin-resistant overweight subjects should be targeted for
weight reduction for prevention of CHD on the grounds of
efficacy.
In Europe, Australasia, and increasingly in the U.S., there
is recognition that clinical intervention for primary preven-
tion of CHD should be based on absolute CHD risk rather
than on the level of any one risk factor (11). Such an
approach acknowledges that the number needed to treat to
prevent an event is a function of absolute, not relative, risk.
Therefore, deciding which overweight patients are most in
need of risk factor intervention will involve consideration of
their entire risk factor profile, not just insulin-resistance
status. Indeed, there is the practical difficulty that the risk
equations, such as the Framingham risk equation (12), that
are being advocated for risk estimation in clinical practice do
not make provision for data on insulin-sensitivity status or
even for plasma insulin levels. To argue that they should
would require that insulin resistance be shown to predict
CHD independently of risk factors with which it is associ-
ated. This remains controversial (13), and no data on this
has been provided by this article.
The article by Abbasi et al. (1) makes an important point
that lean people can be insulin-resistant and that not all
insulin resistance is attributable to obesity. Some obese
individuals may be immune to the adverse metabolic or
cardiovascular effects of obesity. However, targeting those
overweight individuals who are insulin-resistant for risk
factor intervention in clinical practice has both theoretical
and practical limitations. Meanwhile, in the Western world
and in emerging economies, obesity is now so common
across the entire age spectrum that type 2 diabetes is
appearing in children, and not just in children from high-
risk ethnic groups (14). Reversing this increasing imbalance
between energy intake and energy expenditure requires
action at a population level. We know relatively little about
what policies are most cost-effective at shifting the popula-
tion towards greater energy balance, and this is where
research efforts need to be directed in the future.
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